ALKEM — Alkem Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹740.26bn
- IN₹715.76bn
- IN₹126.68bn
- 84
- 13
- 99
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.91 | ||
| PEG Ratio (f) | 1.98 | ||
| EPS Growth (f) | 18.53% | ||
| Dividend Yield (f) | 0.81% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.18 | ||
| Price to Tang. Book | 7.52 | ||
| Price to Free Cashflow | 43.83 | ||
| Price to Sales | 5.81 | ||
| EV to EBITDA | 28.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.66% | ||
| Return on Equity | 21.22% | ||
| Operating Margin | 16.98% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 83,443.6 | 88,650.1 | 106,341.9 | 115,992.6 | 126,675.8 | 137,294.76 | 151,696.96 | 11.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +47.57 | +37.39 | +6.05 | -34.65 | +67.34 | +23.09 | +15.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
Directors
- Basudeo Singh NEC (75)
- Rajesh Dubey CFO (49)
- Amit Ghare CEX (44)
- Girish Jain CEX (50)
- Venkatesh S. CEX (48)
- Manish Narang SVP
- Rajbir Sandhu SVP (54)
- Mukesh Tiwary VPR (49)
- Satyavan Manikani VPR (47)
- K. Prakash VPR (47)
- Ambrish Srivastava VPR (57)
- Sandeep Singh MDR (33)
- Balmiki Singh EDR (60)
- Madhurima Singh EDR
- Mritunjay Singh EDR (52)
- Sarvesh Singh EDR
- Narendra Aneja IND
- Arun Purwar IND (75)
- Sudha Ravi IND (60)
- Dheeraj Sharma IND
- Ranjal Shenoy IND (69)
- Sangeeta Singh IND
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- August 8th, 1973
- Public Since
- December 23rd, 2015
- No. of Employees
- 17,277
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 119,565,000
- Address
- Almac House, Senapati Bapat Marg, MUMBAI, 400013
- Web
- https://www.alkemlabs.com/
- Phone
- +91 2239829999
- Contact
- Purvi Shah
- Auditors
- BSR & Co. LLP
Upcoming Events for ALKEM
Q3 2025 Alkem Laboratories Ltd Earnings Release
Similar to ALKEM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Alkem Laboratories share price?
As of Today at 01:10 UTC, shares in Alkem Laboratories are trading at IN₹6,191.30. This share price information is delayed by 15 minutes.
How has the Alkem Laboratories share price performed this year?
Shares in Alkem Laboratories last closed at IN₹6,191.30 and the price had moved by +72.22% over the past 365 days. In terms of relative price strength the Alkem Laboratories share price has outperformed the S&P BSE 100 Index by +31.83% over the past year.
What are the analyst and broker recommendations for Alkem Laboratories?
The overall consensus recommendation for Alkem Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Alkem Laboratories dividend yield?
The Alkem Laboratories dividend yield is 0.65% based on the trailing twelve month period.
Does Alkem Laboratories pay a dividend?
Last year, Alkem Laboratories paid a total dividend of IN₹40.00, and it currently has a trailing dividend yield of 0.65%. We do not have any data on when Alkem Laboratories is to next pay dividends.
When does Alkem Laboratories next pay dividends?
We do not have data on when Alkem Laboratories is to next pay dividends. The historic dividend yield on Alkem Laboratories shares is currently 0.65%.
How do I buy Alkem Laboratories shares?
To buy shares in Alkem Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alkem Laboratories?
As of the previous close price of IN₹6,191.30, shares in Alkem Laboratories had a market capitalisation of IN₹740.26bn.
Where are Alkem Laboratories shares listed?
Here are the trading details for Alkem Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ALKEM
What kind of share is Alkem Laboratories?
Based on an overall assessment of its quality, value and momentum Alkem Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alkem Laboratories share price forecast for 2024?
The analyst consensus target price for shares in Alkem Laboratories is IN₹5,456.81. That is 11.86% below the last closing price of IN₹6,191.30.
Analysts covering Alkem Laboratories currently have a consensus Earnings Per Share (EPS) forecast of IN₹185.16 for the next financial year.
Find out moreWhat is the trend in the Alkem Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alkem Laboratories. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +15.17%.
As of the last closing price of IN₹6,191.30, shares in Alkem Laboratories were trading +16.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alkem Laboratories PE Ratio?
The Alkem Laboratories PE ratio based on its reported earnings over the past 12 months is 30.91. The shares last closed at IN₹6,191.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alkem Laboratories?
Alkem Laboratories' management team is headed by:
- Basudeo Singh - NEC
- Rajesh Dubey - CFO
- Amit Ghare - CEX
- Girish Jain - CEX
- Venkatesh S. - CEX
- Manish Narang - SVP
- Rajbir Sandhu - SVP
- Mukesh Tiwary - VPR
- Satyavan Manikani - VPR
- K. Prakash - VPR
- Ambrish Srivastava - VPR
- Sandeep Singh - MDR
- Balmiki Singh - EDR
- Madhurima Singh - EDR
- Mritunjay Singh - EDR
- Sarvesh Singh - EDR
- Narendra Aneja - IND
- Arun Purwar - IND
- Sudha Ravi - IND
- Dheeraj Sharma - IND
- Ranjal Shenoy - IND
- Sangeeta Singh - IND